Controversies in the management of gastrointestinal stromal tumors

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue 3, 2014, Pages 216-227

  Yip, Desmond ^a,b   Zalcberg, John ^c,d   Ackland, Stephen ^f,g   Barbour, Andrew P ^h,i   Desai, Jayesh ^c,e   Fox, Stephen ^c   Kotasek, Dusan ^j,k   Mcarthur, Grant ^c   Smithers, B Mark ^h,i  

^a CANBERRA HOSPITAL   (Australia)

^b The Australian National University   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j Adelaide Cancer Centre   (Australia)

^k UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

Adjuvant; Gastrointestinal stromal tumor; Imatinib; Molecular target therapy; Risk stratification

Indexed keywords

CARBONATE DEHYDRATASE II; DASATINIB; DOVITINIB; DOXORUBICIN; EVEROLIMUS; IMATINIB; MASITINIB; NESTIN; NILOTINIB; PROTEIN KINASE C THETA; REGORAFENIB; RETASPIMYCIN; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ADVERSE DRUG REACTION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG MONITORING; DRUG SAFETY; FAILURE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE SEQUENCE; GERMLINE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL CELL OF CAJAL; LONG TERM CARE; MEDICATION COMPLIANCE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANIMAL; DISEASE MANAGEMENT; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; MOLECULARLY TARGETED THERAPY;

ANIMALS; DISEASE MANAGEMENT; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84906230065     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12187     Document Type: Review

References (73)

1. Demetri GD, von Mehren M, Antonescu CR etal. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 (SUPPL 2): S1-41.
2. Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 2012; 9: 351-358.
3. Demetri GD, von Mehren M, Blanke CD etal. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
4. DeMatteo RP, Ballman KV, Antonescu CR etal. Adjuvant imatinib mesylate after resection of localized primary gastrointsestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
5. Zalcberg JR, Desai J, Mann B etal. Consensus approaches to best practice management of gastrointestinal stromal tumors. Asia Pac J Clin Oncol 2008; 4: 188-198.
6. von Mehren M, Benjamin RS, Bui MM etal. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 951-960.
7. Joensuu H, Eriksson M, Sundby Hall K etal. One versus three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265-1272.
8. Wong NA. Gastrointestinal stromal tumours - an update for histopathologists. Histopathology 2011; 59: 807-821.
9. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (SUPPL 7): vii49-55.
10. Demetri GD, Jeffers M, Reichardt P etal. Mutation analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. J Clin Oncol (Meet Abstr) 2013; 31 (SUPPL): Abstract 10503.
11. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol 2010; 3: 461-471.
12. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review of morphology, molecular pathology and prognosis. Semin Diagn Pathol 2006; 23: 70-83.
13. Fletcher CD, Berman JJ, Corless C etal. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465.
14. Rutkowski P, Bylina E, Wozniak A etal. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37: 890-896.
15. Rossi S, Miceli R, Messerini L etal. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35: 1646-1656.
16. Hohenberger P, Ronellenfitsch U, Oladeji O etal. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97: 1854-1859.
17. Joensuu H, Vehtari A, Riihimäki J etal. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-274.
18. Gold JS, Gönen M, Gutiérrez A etal. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-1052.
19. Hemmings C, Yip D. The changing face of GIST. Pathology 2014; 46: 141-148.
20. Hohenberger P, Langer C, Wendtner CM etal. Neoadjuvant treatment of locally advanced GIST: results of APOLLON, a prospective, open label phase II study in KIT-or PDGFRA-positive tumors. J Clin Oncol (Meet Abstr) 2012; 30 (SUPPL): Abstract 10031.
21. McAuliffe JC, Hunt KK, Lazar AJ etal. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16: 910-919.
22. Tielen R, Verhoef C, van Coevorden F etal. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111.
23. Casali PG, Le Cesne A, Poveda-Velasco A etal. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. J Clin Oncol (Meet Abstr) 2013; 31 (SUPPL): Abstract 10500.
24. Blackstein ME, Corless CL, Ballman KV etal. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001. Presented at Gastrointestinal Cancers Symposium 2010; Orlando, Florida: Abstract 6.
25. Blay JY, Pérol D, Le Cesne A. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Ann Oncol 2012; 23: 1659-1665.
26. Medicare Australia. Gastrointestinal Stromal Tumour - Adjuvant. Initial PBS Authority Application. [Cited 19 Feb 2014.] Available from URL: http://www.medicareaustralia.gov.au/provider/pbs/drugs1/files/pb057-1312.pdf.
27. Coreless CL, Ballman KV, Antonescu C etal. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol (Meet Abstr) 2010; 28 (SUPPL): Abstract 10006.
28. Heinrich MC, Owzar K, Corless CL etal. Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
29. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 2010; 28: 1247-1253.
30. Reichardt P, Blay JY, Boukovinas I etal. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol 2012; 23: 2776-2781.
31. Graham J, Debiec-Rychter M, Corless CL, Reid R, Davidson R, White JD. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation. Arch Pathol Lab Med 2007; 131: 1393-1396.
32. Revheim ME, Kristian A, Malinen E etal. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol 2013; 52: 776-782.
33. Le Cesne A, Ray-Coquard I, Bui BN etal. Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol (Meet Abstr) 2010; 28 (SUPPL): Abstract 10033.
34. Domont J, Blay J, Ray-Coquard IL etal. Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: result of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol (Meet Abstr) 2011; 29 (SUPPL): Abstract 10054.
35. Bardsley MR, Horváth VJ, Asuzu DT etal. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139: 942-952.
36. Tielen R, Verhoef C, van Coevorden F etal. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol 2013; 39: 150-155.
37. von Mehren M, Heinrich MC, Joensuu H, Blanke CD, Wehrle E, Demetri GD. Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol (Meet Abstr) 2011; 29 (SUPPL): Abstract 10016.
38. Patel S. Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol 2013; 72: 277-286.
39. Gambacorti-Passerini C, Antolini L, Mahon FX etal. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553-561.
40. Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 2012; 86: 1-12.
41. Halpern R, Barghou V, Williams D. Relationship between compliance with imatinib mesylate and medical costs for patients with CML and GIST. J Clin Oncol (Meet Abstr) 2007; 25 (SUPPL 18S): Abstract 6618.
42. Mazzeo F, Duck L, Joosens E etal. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 2011; 31: 1407-1409.
43. Demetri GD, Wang Y, Wehrle E etal. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141-3147.
44. Widmer N, Decosterd LA, Csajka C etal. Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer 2010; 102: 1198-1199.
45. Eechoute K, Fransson MN, Reyners AK etal. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012; 18: 5780-5787.
46. Eechoute K, Sparreboom A, Burger H etal. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011; 17: 406-415.
47. Yoo C, Ryu MH, Ryoo BY etal. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest New Drugs 2012; 30: 1703-1708.
48. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357-371.
49. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-2506.
50. Hislop J, Mowatt G, Sharma P etal. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer 2012; 43: 168-176.
51. Demetri GD, van Oosterom AT, Garrett CR etal. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
52. George S, Blay JY, Casali PG etal. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45: 1959-1968.
53. Motzer RJ, Hutson TE, Olsen MR etal. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30: 1371-1377.
54. Li J, Gao J, Hong J, Shen L. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Future Oncol 2012; 8: 617-624.
55. Heinrich MC, Maki RG, Corless CL etal. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
56. Demetri GD, Reichardt P, Kang YK etal. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302.
57. George S, Wang Q, Heinrich MC etal. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401-2407.
58. Reichardt P, Blay JY, Gelderblom H etal. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23: 1680-1687.
59. Trent JC, Wathen K, von Mehren M etal. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (Meet Abstr) 2011; 29 (SUPPL): Abstract 10006.
60. Kindler HL, Campbell NP, Wroblewski K etal. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). J Clin Oncol (Meet Abstr) 2011; 29 (SUPPL): Abstract 10009.
61. Kang YK, Yoo C, Ryoo BY etal. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer 2013; 109: 2309-2315.
62. Blay J, Casali PG, Reichardt P etal. Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST). Presented at European Cancer Congress 2013; Amsterdam, Netherlands. Abstract 3827.
63. Italiano A, Cioffi A, Coco P etal. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 2012; 19: 1551-1559.
64. Kang YK, Ryu MH, Yoo C etal. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14: 1175-1182.
65. Bracci R, Maccaroni E, Cascinu S. Transient sunitinib resistance in gastrointestinal stromal tumors. N Engl J Med 2013; 368: 2042-2043.
66. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011; 38 (SUPPL 1): S10-19.
67. Heinrich MC, Griffith D, McKinley A etal. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 4375-4384.
68. Blay JY, Shen L, Kang YK etal. Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST). J Clin Oncol (Meet Abstr) 2013; 31 (SUPPL): Abstract 10501.
69. Demetri G, Le Cesne A, von Mehren M etal. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of tyrosine kinase inhibitor (TKI) therapies. Presented at Gastrointestinal Cancers Symposium 2010; Orlando, Florida. Abstract 64.
70. Schöffski P, Reichardt P, Blay JY etal. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010; 21: 1990-1998.
71. Maurel J, Martins AS, Poveda A etal. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010; 116: 3692-3701.
72. Blesius A, Cassier PA, Ray-Coquard IL etal. Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol (Meet Abstr) 2011; 29 (SUPPL): Abstract 10048.
73. Nannini M, Biasco G, Pallotti MC etal. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. Med Oncol 2012; 29: 144-150.